Tripep carries out new issues of shares of in total SEK 9.9 million

Tripep carries out new issues of shares of in total SEK 9.9 million

Tripep has carried out a private placement of 4 million shares at a subscription
price of SEK 1.25 per share. Tripep raises SEK 5 million through the placement.

On November 3 2008 the Board of Directors of Tripep has, based on the
authorization by the Annual General Meeting resolved to carry out a rights
issue. If the rights issue is fully subscribed, Tripep will raise almost SEK 4.9
million. The 4 million shares that are issued in the private placement do not
carry right to participate in the rights issue. 

”Tripep can raise almost SEK 10 million through these new issues of shares and
these contributions together with our significantly reduced cost mass, means
that we can be on terra firma again”, says Jan Nilsson, CEO of Tripep.

Terms and conditions for the rights issue 
• The number of shares to be issued shall not exceed 9,786,224 
• The subscription price shall be SEK 0.50 per share 
• Each existing share shall entitle to subscription for one new share 

Time plan for the new issue 
• Last day for trading in the share including the right to participate in the
new issue is Wednesday, 5 November, 2008 
• The record date is 10 November, 2008 
• The period for subscription with or without pre-emption rights is 14 - 28
November 2008 
• Trading in subscription rights takes place during the period 14 November -25
November, 2008 
• Trading in interim shares (BTA) takes place from 14 November until the rights
issue has been registered by the Swedish Company Office


The proceeds from the rights issue is less than one million Euro. In accordance
with current prospectus rules no prospectus will be prepared.
The new issue is carried out without any guarantees or undertakings by existing
shareholders to subscribe.

For more information, please contact:
Jan Nilsson, CEO, Tripep AB			
Tel: +46 8 449 84 80, Mobile phone: +46 70 466 31 63          		
E-mail: jan.nilsson@tripep.se	

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.